Lazard Asset Management
MEDP icon

Lazard Asset Management’s Medpace MEDP Stock Holding History

Lazard Asset Management’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.15M Sell
15,382
-10,258
-40% -$4.73M 0.01% 487
2026
Q1 		$12.3M Buy
25,640
+5,602
+28% +$2.87M 0.02% 395
2025
Q4 		$11.3M Buy
20,038
+8,372
+72% +$4.75M 0.02% 394
2025
Q3 		$6M Buy
11,666
+3,835
+49% +$1.67M 0.01% 531
2025
Q2 		$2.46M Sell
7,831
-19,981
-72% -$6M ﹤0.01% 944
2025
Q1 		$8.47M Sell
27,812
-298
-1% -$100K 0.01% 528
2024
Q4 		$9.34M Buy
28,110
+3,303
+13% +$1.12M 0.01% 485
2024
Q3 		$8.28M Sell
24,807
-49,578
-67% -$18.8M 0.01% 499
2024
Q2 		$30.6M Buy
74,385
+2,109
+3% +$835K 0.04% 295
2024
Q1 		$29.2M Sell
72,276
-10,680
-13% -$3.75M 0.04% 313
2023
Q4 		$25.4M Buy
82,956
+665
+0.8% +$180K 0.03% 335
2023
Q3 		$19.9M Buy
82,291
+2,110
+3% +$540K 0.03% 379
2023
Q2 		$19.3M Sell
80,181
-14,269
-15% -$2.96M 0.02% 410
2023
Q1 		$17.8M Buy
94,450
+12,598
+15% +$2.61M 0.02% 449
2022
Q4 		$17.4M Buy
81,852
+66,600
+437% +$13.3M 0.02% 450
2022
Q3 		$2.4M Buy
15,252
+13,014
+582% +$2.08M ﹤0.01% 847
2022
Q2 		$334K Buy
2,238
+1,547
+224% +$224K ﹤0.01% 1178
2022
Q1 		$113K Sell
691
-412
-37% -$67.9K ﹤0.01% 1364
2021
Q4 		$239K Sell
1,103
-13,201
-92% -$2.76M ﹤0.01% 1241
2021
Q3 		$2.71M Buy
+14,304
New +$2.61M ﹤0.01% 876
2021
Q2 		– Sell
-781
Closed -$128K – 2027
2021
Q1 		$128K Buy
781
+252
+48% +$38.5K ﹤0.01% 1167
2020
Q4 		$73K Hold
529
– – ﹤0.01% 1273
2020
Q3 		$59K Sell
529
-334
-39% -$38.6K ﹤0.01% 1133
2020
Q2 		$80K Sell
863
-423
-33% -$36K ﹤0.01% 1076
2020
Q1 		$94K Buy
1,286
+513
+66% +$44.5K ﹤0.01% 1011
2019
Q4 		$64K Buy
773
+380
+97% +$29.4K ﹤0.01% 1012
2019
Q3 		$33K Buy
+393
New +$29.7K ﹤0.01% 1019

Other funds holding MEDP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Lazard Asset Management's MEDP Position: Q2 2026 in Review

Lazard Asset Management reduced its Medpace (MEDP) stake by 40% in Q2 2026, selling an estimated $4.73M and leaving 15,382 shares worth $8.15M. The position accounts for 0.01% of the portfolio, ranked #487.

Lazard Asset Management first reported a position in MEDP in Q3 2019 and has held it in 27 quarters since. The position peaked at $30.6M in Q2 2024. 698 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Lazard Asset Management held 15,382 shares of Medpace worth $8.15M as of Q2 2026.
  • Lazard Asset Management sold 10,258 Medpace shares in Q2 2026, an estimated $4.73M.
  • Medpace made up 0.01% of Lazard Asset Management's portfolio in Q2 2026, its #487 holding.
  • Lazard Asset Management first reported a position in Medpace in Q3 2019 and has held it in 27 quarters since.
  • Lazard Asset Management's Medpace position peaked at $30.6M in Q2 2024.
  • 698 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.